Sign In
Buy VTGN
$0.560
-0.0199 (-3.43%)
At Close: Jun 03, 2026
Investors who lost money on Vistagen Therapeutics, Inc.(VTGN) should contact The Gross Law Firm about pending Class Action - VTGN
09:00am, Thursday, 05'th Feb 2026
NEW YORK, Feb. 5, 2026 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Vistagen Therapeutics, Inc. (NASDAQ: VTGN). Shareholders who purchased shares of VTGN during t
Portnoy Law Firm Announces Class Action on Behalf of Vistagen Therapeutics, Inc. Investors
09:00am, Thursday, 05'th Feb 2026
LOS ANGELES, Feb. 05, 2026 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Vistagen Therapeutics, Inc., (“Vistagen” or the "Company") (NASDAQ: VTGN) investors off a class action on behalf of inv
Vistagen Therapeutics, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - VTGN
05:19am, Thursday, 05'th Feb 2026
LOS ANGELES, Feb. 5, 2026 /PRNewswire/ -- The DJS Law Group reminds investors of a class action lawsuit against Vistagen Therapeutics, Inc. ("Vistagen " or "the Company") (NASDAQ: VTGN ) for viol
VTGN Investors Have Opportunity to Lead Vistagen Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm
04:34am, Thursday, 05'th Feb 2026
LOS ANGELES, Feb. 5, 2026 /PRNewswire/ -- The Schall Law Firm , a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Vistagen Therapeutics, Inc. ("Vistag
VistaGen Therapeutics (VTGN) to Release Quarterly Earnings on Thursday
02:02am, Thursday, 05'th Feb 2026
VistaGen Therapeutics (NASDAQ: VTGN - Get Free Report) is anticipated to release its Q3 2026 results before the market opens on Thursday, February 12th. Analysts expect VistaGen Therapeutics to post e
SAN DIEGO, Feb. 4, 2026 /PRNewswire/ -- Robbins LLP reminds investors that a class action was filed on behalf of all investors who purchased or otherwise acquired Vistagen Therapeutics, Inc. (NASDAQ:
Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Vistagen (VTGN) To Contact Him Directly To Discuss Their Options
NEW YORK, Feb. 04, 2026 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Vistagen Therapeutics, Inc. (NASDAQ: VTGN).
NEW YORK, Feb. 04, 2026 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Vistagen Therapeutics, Inc. (NASDAQ: VTGN) between April 1, 20
New York, New York--(Newsfile Corp. - February 4, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Vistagen Therapeutics, Inc. (NASDAQ: VTGN) betw
March 16, 2026 Deadline: Contact Levi & Korsinsky to Join Class Action Suit Against VTGN
02:50pm, Wednesday, 04'th Feb 2026
NEW YORK, Feb. 4, 2026 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Vistagen Therapeutics, Inc. ("Vistagen" or the "Company") (NASDAQ: VTGN) of a class action securities lawsuit. CLASS
VTGN INVESTOR ALERT -- LEVI & KORSINSKY, LLP ANNOUNCES CLASS ACTION OVER ALLEGED MISLEADING STATEMENTS ABOUT CLINICAL TRIAL PROGRESS
02:46pm, Wednesday, 04'th Feb 2026
VTGN INVESTOR ALERT — March 16, 2026 DEADLINE NEW YORK, Feb. 4, 2026 /PRNewswire/ -- Levi & Korsinsky, LLP alerts investors in Vistagen Therapeutics, Inc. (NASDAQ: VTGN) of a pending securities clas
UPCOMING DEADLINE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Vistagen Therapeutics
02:21pm, Wednesday, 04'th Feb 2026
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered In Vistagen To Contact Him Directly To Discuss Their Options
Vistagen to Report Fiscal Year 2026 Third Quarter Results and Host Corporate Update Conference Call on February 12, 2026
08:30am, Wednesday, 04'th Feb 2026
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commerci
ATLANTA, Feb. 04, 2026 (GLOBE NEWSWIRE) -- A shareholder class action lawsuit has been filed against Vistagen Therapeutics, Inc. (“Vistagen” or the “Company”) (NASDAQ: VTGN). The lawsuit alleg
